SCHEMBL3378656

SCHEMBL3378656

COC(=O)c1cc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2-n2ccc(C(F)(F)F)n2)cnc1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 1/20 0.37
SYK P43405 2/20 0.36
EGFR P00533 3/20 0.36
MAPT P10636 2/20 0.36
CSNK2A1 P68400 1/20 0.36
APP P05067 1/20 0.36
TYRO3 Q06418 2/20 0.36
MERTK Q12866 2/20 0.36
CSF1R P07333 1/20 0.36
ULK1 O75385 1/20 0.36
AXL P30530 1/20 0.36
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
STK17B O94768 1/20 0.35
STK17A Q9UEE5 1/20 0.35
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3448901 0.94 EGFR (0.41) PTK2SYKEGFRCSNK2A1APP
SCHEMBL3451173 0.93 CSF1R (0.42) PTK2SYKEGFRCSF1RSTK17B
SCHEMBL13312701 0.93 SCN9A (0.37) PTK2SYKEGFRPIK3CDPIK3CA
SCHEMBL3447244 0.92 PTK2 (0.42) PTK2APPMERTKULK1AXL
SCHEMBL3449613 0.92 PTK2 (0.37) PTK2SYKEGFRAPPCSF1R
SCHEMBL3449292 0.92 NTRK1 (0.39) PTK2SYKMAPTCSNK2A1CSF1R
SCHEMBL3448841 0.91 TYRO3 (0.42) PTK2SYKEGFRMAPTTYRO3
SCHEMBL3446985 0.91 MAPT (0.45) SYKMAPTTYRO3MERTKNPSR1
SCHEMBL3450457 0.90 SCN9A (0.46)
SCHEMBL3450339 0.89 SCN9A (0.41) EGFRPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD PTK2 3971/4885SYK 804/4885EGFR 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.